nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—CYP3A7—Progesterone—uterine cancer	0.0873	0.189	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Progesterone—uterine cancer	0.0873	0.189	CbGbCtD
Tacrolimus—CYP3A5—Progesterone—uterine cancer	0.0655	0.142	CbGbCtD
Tacrolimus—ABCB1—Progesterone—uterine cancer	0.0426	0.0924	CbGbCtD
Tacrolimus—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0385	0.0836	CbGbCtD
Tacrolimus—ABCB1—Dactinomycin—uterine cancer	0.0338	0.0733	CbGbCtD
Tacrolimus—CYP3A5—Etoposide—uterine cancer	0.0293	0.0635	CbGbCtD
Tacrolimus—CYP3A4—Progesterone—uterine cancer	0.0255	0.0554	CbGbCtD
Tacrolimus—ABCB1—Etoposide—uterine cancer	0.0191	0.0414	CbGbCtD
Tacrolimus—ABCB1—Doxorubicin—uterine cancer	0.013	0.0282	CbGbCtD
Tacrolimus—CYP3A4—Etoposide—uterine cancer	0.0114	0.0248	CbGbCtD
Tacrolimus—CYP3A4—Doxorubicin—uterine cancer	0.00779	0.0169	CbGbCtD
Tacrolimus—ABCA5—myometrium—uterine cancer	0.00531	0.0474	CbGeAlD
Tacrolimus—ABCA5—uterine cervix—uterine cancer	0.00413	0.0369	CbGeAlD
Tacrolimus—ABCA5—decidua—uterine cancer	0.00394	0.0351	CbGeAlD
Tacrolimus—ABCA5—endometrium—uterine cancer	0.00374	0.0334	CbGeAlD
Tacrolimus—ABCA5—mammalian vulva—uterine cancer	0.00362	0.0323	CbGeAlD
Tacrolimus—PPP3CA—myometrium—uterine cancer	0.00359	0.032	CbGeAlD
Tacrolimus—ABCA5—female reproductive system—uterine cancer	0.0031	0.0276	CbGeAlD
Tacrolimus—ABCA5—female gonad—uterine cancer	0.00282	0.0251	CbGeAlD
Tacrolimus—ABCA5—vagina—uterine cancer	0.0028	0.025	CbGeAlD
Tacrolimus—PPP3CA—uterine cervix—uterine cancer	0.00279	0.0249	CbGeAlD
Tacrolimus—PPP3CA—smooth muscle tissue—uterine cancer	0.00271	0.0242	CbGeAlD
Tacrolimus—PPP3CA—decidua—uterine cancer	0.00266	0.0237	CbGeAlD
Tacrolimus—MTOR—myometrium—uterine cancer	0.00265	0.0237	CbGeAlD
Tacrolimus—PPP3CA—renal system—uterine cancer	0.00261	0.0233	CbGeAlD
Tacrolimus—PPP3CA—endometrium—uterine cancer	0.00252	0.0225	CbGeAlD
Tacrolimus—PPP3CA—mammalian vulva—uterine cancer	0.00244	0.0218	CbGeAlD
Tacrolimus—FKBP1A—myometrium—uterine cancer	0.00238	0.0213	CbGeAlD
Tacrolimus—PPP3CA—uterus—uterine cancer	0.00233	0.0208	CbGeAlD
Tacrolimus—PPP3CA—female reproductive system—uterine cancer	0.00209	0.0187	CbGeAlD
Tacrolimus—MTOR—epithelium—uterine cancer	0.00208	0.0186	CbGeAlD
Tacrolimus—MTOR—smooth muscle tissue—uterine cancer	0.002	0.0179	CbGeAlD
Tacrolimus—MTOR—renal system—uterine cancer	0.00193	0.0172	CbGeAlD
Tacrolimus—PPP3CA—female gonad—uterine cancer	0.0019	0.017	CbGeAlD
Tacrolimus—PPP3CA—vagina—uterine cancer	0.00189	0.0169	CbGeAlD
Tacrolimus—FKBP1A—epithelium—uterine cancer	0.00187	0.0167	CbGeAlD
Tacrolimus—MTOR—endometrium—uterine cancer	0.00187	0.0166	CbGeAlD
Tacrolimus—FKBP1A—uterine cervix—uterine cancer	0.00185	0.0166	CbGeAlD
Tacrolimus—ABCA5—lymph node—uterine cancer	0.00181	0.0162	CbGeAlD
Tacrolimus—MTOR—mammalian vulva—uterine cancer	0.0018	0.0161	CbGeAlD
Tacrolimus—FKBP1A—smooth muscle tissue—uterine cancer	0.0018	0.0161	CbGeAlD
Tacrolimus—FKBP1A—decidua—uterine cancer	0.00177	0.0158	CbGeAlD
Tacrolimus—FKBP1A—renal system—uterine cancer	0.00174	0.0155	CbGeAlD
Tacrolimus—MTOR—uterus—uterine cancer	0.00172	0.0153	CbGeAlD
Tacrolimus—FKBP1A—endometrium—uterine cancer	0.00168	0.015	CbGeAlD
Tacrolimus—FKBP1A—mammalian vulva—uterine cancer	0.00162	0.0145	CbGeAlD
Tacrolimus—FKBP1A—uterus—uterine cancer	0.00155	0.0138	CbGeAlD
Tacrolimus—MTOR—female reproductive system—uterine cancer	0.00155	0.0138	CbGeAlD
Tacrolimus—MTOR—female gonad—uterine cancer	0.00141	0.0125	CbGeAlD
Tacrolimus—MTOR—vagina—uterine cancer	0.0014	0.0125	CbGeAlD
Tacrolimus—FKBP1A—female reproductive system—uterine cancer	0.00139	0.0124	CbGeAlD
Tacrolimus—ORM1—endometrium—uterine cancer	0.00131	0.0117	CbGeAlD
Tacrolimus—FKBP1A—female gonad—uterine cancer	0.00126	0.0113	CbGeAlD
Tacrolimus—FKBP1A—vagina—uterine cancer	0.00126	0.0112	CbGeAlD
Tacrolimus—PPP3CA—lymph node—uterine cancer	0.00122	0.0109	CbGeAlD
Tacrolimus—ORM1—female reproductive system—uterine cancer	0.00109	0.00971	CbGeAlD
Tacrolimus—MTOR—lymph node—uterine cancer	0.000904	0.00807	CbGeAlD
Tacrolimus—FKBP1A—lymph node—uterine cancer	0.000813	0.00726	CbGeAlD
Tacrolimus—CYP3A5—uterine cervix—uterine cancer	0.000808	0.00721	CbGeAlD
Tacrolimus—CYP3A5—renal system—uterine cancer	0.000756	0.00674	CbGeAlD
Tacrolimus—ORM1—lymph node—uterine cancer	0.000636	0.00568	CbGeAlD
Tacrolimus—CYP3A4—renal system—uterine cancer	0.000567	0.00506	CbGeAlD
Tacrolimus—ALB—lymph node—uterine cancer	0.000558	0.00498	CbGeAlD
Tacrolimus—ABCB1—myometrium—uterine cancer	0.000551	0.00492	CbGeAlD
Tacrolimus—CYP3A5—female gonad—uterine cancer	0.000551	0.00491	CbGeAlD
Tacrolimus—CYP3A5—vagina—uterine cancer	0.000547	0.00488	CbGeAlD
Tacrolimus—CYP3A4—female reproductive system—uterine cancer	0.000454	0.00405	CbGeAlD
Tacrolimus—ABCB1—epithelium—uterine cancer	0.000433	0.00386	CbGeAlD
Tacrolimus—ABCB1—uterine cervix—uterine cancer	0.000429	0.00383	CbGeAlD
Tacrolimus—ABCB1—decidua—uterine cancer	0.000409	0.00365	CbGeAlD
Tacrolimus—ABCB1—renal system—uterine cancer	0.000401	0.00358	CbGeAlD
Tacrolimus—ABCB1—endometrium—uterine cancer	0.000388	0.00346	CbGeAlD
Tacrolimus—ABCB1—mammalian vulva—uterine cancer	0.000375	0.00335	CbGeAlD
Tacrolimus—ABCB1—uterus—uterine cancer	0.000358	0.00319	CbGeAlD
Tacrolimus—ABCB1—female reproductive system—uterine cancer	0.000321	0.00287	CbGeAlD
Tacrolimus—ABCB1—female gonad—uterine cancer	0.000293	0.00261	CbGeAlD
Tacrolimus—ABCB1—vagina—uterine cancer	0.000291	0.00259	CbGeAlD
Tacrolimus—ABCB1—lymph node—uterine cancer	0.000188	0.00168	CbGeAlD
Tacrolimus—Pancreatitis—Doxorubicin—uterine cancer	9.68e-05	0.000319	CcSEcCtD
Tacrolimus—Weight decreased—Epirubicin—uterine cancer	9.65e-05	0.000318	CcSEcCtD
Tacrolimus—Dyspnoea—Etoposide—uterine cancer	9.65e-05	0.000318	CcSEcCtD
Tacrolimus—Hyperglycaemia—Epirubicin—uterine cancer	9.62e-05	0.000317	CcSEcCtD
Tacrolimus—Somnolence—Etoposide—uterine cancer	9.62e-05	0.000317	CcSEcCtD
Tacrolimus—Angina pectoris—Doxorubicin—uterine cancer	9.61e-05	0.000317	CcSEcCtD
Tacrolimus—Pneumonia—Epirubicin—uterine cancer	9.57e-05	0.000315	CcSEcCtD
Tacrolimus—Infestation NOS—Epirubicin—uterine cancer	9.51e-05	0.000314	CcSEcCtD
Tacrolimus—Infestation—Epirubicin—uterine cancer	9.51e-05	0.000314	CcSEcCtD
Tacrolimus—Vomiting—Dactinomycin—uterine cancer	9.51e-05	0.000313	CcSEcCtD
Tacrolimus—Bronchitis—Doxorubicin—uterine cancer	9.49e-05	0.000313	CcSEcCtD
Tacrolimus—Stevens-Johnson syndrome—Epirubicin—uterine cancer	9.43e-05	0.000311	CcSEcCtD
Tacrolimus—Rash—Dactinomycin—uterine cancer	9.43e-05	0.000311	CcSEcCtD
Tacrolimus—Decreased appetite—Etoposide—uterine cancer	9.41e-05	0.00031	CcSEcCtD
Tacrolimus—Pancytopenia—Doxorubicin—uterine cancer	9.37e-05	0.000309	CcSEcCtD
Tacrolimus—Renal failure—Epirubicin—uterine cancer	9.35e-05	0.000308	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Etoposide—uterine cancer	9.34e-05	0.000308	CcSEcCtD
Tacrolimus—Fatigue—Etoposide—uterine cancer	9.33e-05	0.000308	CcSEcCtD
Tacrolimus—Neuropathy peripheral—Epirubicin—uterine cancer	9.32e-05	0.000307	CcSEcCtD
Tacrolimus—Jaundice—Epirubicin—uterine cancer	9.27e-05	0.000306	CcSEcCtD
Tacrolimus—Stomatitis—Epirubicin—uterine cancer	9.27e-05	0.000306	CcSEcCtD
Tacrolimus—Constipation—Etoposide—uterine cancer	9.25e-05	0.000305	CcSEcCtD
Tacrolimus—Pain—Etoposide—uterine cancer	9.25e-05	0.000305	CcSEcCtD
Tacrolimus—Conjunctivitis—Epirubicin—uterine cancer	9.24e-05	0.000305	CcSEcCtD
Tacrolimus—Urinary tract infection—Epirubicin—uterine cancer	9.24e-05	0.000305	CcSEcCtD
Tacrolimus—Dysuria—Doxorubicin—uterine cancer	9.23e-05	0.000304	CcSEcCtD
Tacrolimus—Neutropenia—Doxorubicin—uterine cancer	9.23e-05	0.000304	CcSEcCtD
Tacrolimus—Sweating—Epirubicin—uterine cancer	9.12e-05	0.000301	CcSEcCtD
Tacrolimus—Pollakiuria—Doxorubicin—uterine cancer	9.12e-05	0.000301	CcSEcCtD
Tacrolimus—Haematuria—Epirubicin—uterine cancer	9.07e-05	0.000299	CcSEcCtD
Tacrolimus—Photosensitivity reaction—Doxorubicin—uterine cancer	9.01e-05	0.000297	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Epirubicin—uterine cancer	8.99e-05	0.000297	CcSEcCtD
Tacrolimus—Weight increased—Doxorubicin—uterine cancer	8.98e-05	0.000296	CcSEcCtD
Tacrolimus—Epistaxis—Epirubicin—uterine cancer	8.97e-05	0.000296	CcSEcCtD
Tacrolimus—Weight decreased—Doxorubicin—uterine cancer	8.93e-05	0.000294	CcSEcCtD
Tacrolimus—Sinusitis—Epirubicin—uterine cancer	8.92e-05	0.000294	CcSEcCtD
Tacrolimus—Feeling abnormal—Etoposide—uterine cancer	8.92e-05	0.000294	CcSEcCtD
Tacrolimus—Hyperglycaemia—Doxorubicin—uterine cancer	8.9e-05	0.000294	CcSEcCtD
Tacrolimus—Nausea—Dactinomycin—uterine cancer	8.88e-05	0.000293	CcSEcCtD
Tacrolimus—Agranulocytosis—Epirubicin—uterine cancer	8.87e-05	0.000293	CcSEcCtD
Tacrolimus—Pneumonia—Doxorubicin—uterine cancer	8.85e-05	0.000292	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Etoposide—uterine cancer	8.85e-05	0.000292	CcSEcCtD
Tacrolimus—Infestation NOS—Doxorubicin—uterine cancer	8.8e-05	0.00029	CcSEcCtD
Tacrolimus—Infestation—Doxorubicin—uterine cancer	8.8e-05	0.00029	CcSEcCtD
Tacrolimus—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	8.72e-05	0.000288	CcSEcCtD
Tacrolimus—Bradycardia—Epirubicin—uterine cancer	8.69e-05	0.000287	CcSEcCtD
Tacrolimus—Renal failure—Doxorubicin—uterine cancer	8.65e-05	0.000285	CcSEcCtD
Tacrolimus—Neuropathy peripheral—Doxorubicin—uterine cancer	8.63e-05	0.000284	CcSEcCtD
Tacrolimus—Urticaria—Etoposide—uterine cancer	8.6e-05	0.000283	CcSEcCtD
Tacrolimus—Haemoglobin—Epirubicin—uterine cancer	8.58e-05	0.000283	CcSEcCtD
Tacrolimus—Stomatitis—Doxorubicin—uterine cancer	8.58e-05	0.000283	CcSEcCtD
Tacrolimus—Jaundice—Doxorubicin—uterine cancer	8.58e-05	0.000283	CcSEcCtD
Tacrolimus—Rhinitis—Epirubicin—uterine cancer	8.56e-05	0.000282	CcSEcCtD
Tacrolimus—Abdominal pain—Etoposide—uterine cancer	8.55e-05	0.000282	CcSEcCtD
Tacrolimus—Body temperature increased—Etoposide—uterine cancer	8.55e-05	0.000282	CcSEcCtD
Tacrolimus—Conjunctivitis—Doxorubicin—uterine cancer	8.55e-05	0.000282	CcSEcCtD
Tacrolimus—Urinary tract infection—Doxorubicin—uterine cancer	8.55e-05	0.000282	CcSEcCtD
Tacrolimus—Haemorrhage—Epirubicin—uterine cancer	8.54e-05	0.000281	CcSEcCtD
Tacrolimus—Hepatitis—Epirubicin—uterine cancer	8.54e-05	0.000281	CcSEcCtD
Tacrolimus—Hypoaesthesia—Epirubicin—uterine cancer	8.49e-05	0.00028	CcSEcCtD
Tacrolimus—Pharyngitis—Epirubicin—uterine cancer	8.47e-05	0.000279	CcSEcCtD
Tacrolimus—Sweating—Doxorubicin—uterine cancer	8.44e-05	0.000278	CcSEcCtD
Tacrolimus—Urinary tract disorder—Epirubicin—uterine cancer	8.43e-05	0.000278	CcSEcCtD
Tacrolimus—Oedema peripheral—Epirubicin—uterine cancer	8.41e-05	0.000277	CcSEcCtD
Tacrolimus—Haematuria—Doxorubicin—uterine cancer	8.39e-05	0.000277	CcSEcCtD
Tacrolimus—Connective tissue disorder—Epirubicin—uterine cancer	8.39e-05	0.000277	CcSEcCtD
Tacrolimus—Urethral disorder—Epirubicin—uterine cancer	8.37e-05	0.000276	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Doxorubicin—uterine cancer	8.32e-05	0.000274	CcSEcCtD
Tacrolimus—Epistaxis—Doxorubicin—uterine cancer	8.3e-05	0.000274	CcSEcCtD
Tacrolimus—Sinusitis—Doxorubicin—uterine cancer	8.26e-05	0.000272	CcSEcCtD
Tacrolimus—Visual impairment—Epirubicin—uterine cancer	8.23e-05	0.000271	CcSEcCtD
Tacrolimus—Agranulocytosis—Doxorubicin—uterine cancer	8.21e-05	0.000271	CcSEcCtD
Tacrolimus—Erythema multiforme—Epirubicin—uterine cancer	8.07e-05	0.000266	CcSEcCtD
Tacrolimus—Bradycardia—Doxorubicin—uterine cancer	8.04e-05	0.000265	CcSEcCtD
Tacrolimus—Eye disorder—Epirubicin—uterine cancer	7.98e-05	0.000263	CcSEcCtD
Tacrolimus—Hypersensitivity—Etoposide—uterine cancer	7.97e-05	0.000263	CcSEcCtD
Tacrolimus—Tinnitus—Epirubicin—uterine cancer	7.96e-05	0.000262	CcSEcCtD
Tacrolimus—Haemoglobin—Doxorubicin—uterine cancer	7.94e-05	0.000262	CcSEcCtD
Tacrolimus—Flushing—Epirubicin—uterine cancer	7.92e-05	0.000261	CcSEcCtD
Tacrolimus—Cardiac disorder—Epirubicin—uterine cancer	7.92e-05	0.000261	CcSEcCtD
Tacrolimus—Rhinitis—Doxorubicin—uterine cancer	7.92e-05	0.000261	CcSEcCtD
Tacrolimus—Hepatitis—Doxorubicin—uterine cancer	7.9e-05	0.00026	CcSEcCtD
Tacrolimus—Haemorrhage—Doxorubicin—uterine cancer	7.9e-05	0.00026	CcSEcCtD
Tacrolimus—Hypoaesthesia—Doxorubicin—uterine cancer	7.86e-05	0.000259	CcSEcCtD
Tacrolimus—Pharyngitis—Doxorubicin—uterine cancer	7.84e-05	0.000259	CcSEcCtD
Tacrolimus—Urinary tract disorder—Doxorubicin—uterine cancer	7.8e-05	0.000257	CcSEcCtD
Tacrolimus—Oedema peripheral—Doxorubicin—uterine cancer	7.78e-05	0.000257	CcSEcCtD
Tacrolimus—Asthenia—Etoposide—uterine cancer	7.76e-05	0.000256	CcSEcCtD
Tacrolimus—Connective tissue disorder—Doxorubicin—uterine cancer	7.76e-05	0.000256	CcSEcCtD
Tacrolimus—Angiopathy—Epirubicin—uterine cancer	7.75e-05	0.000255	CcSEcCtD
Tacrolimus—Urethral disorder—Doxorubicin—uterine cancer	7.74e-05	0.000255	CcSEcCtD
Tacrolimus—Immune system disorder—Epirubicin—uterine cancer	7.71e-05	0.000254	CcSEcCtD
Tacrolimus—Mediastinal disorder—Epirubicin—uterine cancer	7.69e-05	0.000254	CcSEcCtD
Tacrolimus—Chills—Epirubicin—uterine cancer	7.66e-05	0.000253	CcSEcCtD
Tacrolimus—Pruritus—Etoposide—uterine cancer	7.66e-05	0.000252	CcSEcCtD
Tacrolimus—Arrhythmia—Epirubicin—uterine cancer	7.63e-05	0.000251	CcSEcCtD
Tacrolimus—Visual impairment—Doxorubicin—uterine cancer	7.61e-05	0.000251	CcSEcCtD
Tacrolimus—Alopecia—Epirubicin—uterine cancer	7.54e-05	0.000249	CcSEcCtD
Tacrolimus—Mental disorder—Epirubicin—uterine cancer	7.48e-05	0.000247	CcSEcCtD
Tacrolimus—Erythema multiforme—Doxorubicin—uterine cancer	7.47e-05	0.000246	CcSEcCtD
Tacrolimus—Malnutrition—Epirubicin—uterine cancer	7.43e-05	0.000245	CcSEcCtD
Tacrolimus—Erythema—Epirubicin—uterine cancer	7.43e-05	0.000245	CcSEcCtD
Tacrolimus—Diarrhoea—Etoposide—uterine cancer	7.4e-05	0.000244	CcSEcCtD
Tacrolimus—Eye disorder—Doxorubicin—uterine cancer	7.38e-05	0.000243	CcSEcCtD
Tacrolimus—Tinnitus—Doxorubicin—uterine cancer	7.37e-05	0.000243	CcSEcCtD
Tacrolimus—Flushing—Doxorubicin—uterine cancer	7.33e-05	0.000242	CcSEcCtD
Tacrolimus—Cardiac disorder—Doxorubicin—uterine cancer	7.33e-05	0.000242	CcSEcCtD
Tacrolimus—Flatulence—Epirubicin—uterine cancer	7.32e-05	0.000241	CcSEcCtD
Tacrolimus—Tension—Epirubicin—uterine cancer	7.29e-05	0.00024	CcSEcCtD
Tacrolimus—Dysgeusia—Epirubicin—uterine cancer	7.28e-05	0.00024	CcSEcCtD
Tacrolimus—Nervousness—Epirubicin—uterine cancer	7.22e-05	0.000238	CcSEcCtD
Tacrolimus—Back pain—Epirubicin—uterine cancer	7.19e-05	0.000237	CcSEcCtD
Tacrolimus—Angiopathy—Doxorubicin—uterine cancer	7.17e-05	0.000236	CcSEcCtD
Tacrolimus—Dizziness—Etoposide—uterine cancer	7.16e-05	0.000236	CcSEcCtD
Tacrolimus—Muscle spasms—Epirubicin—uterine cancer	7.15e-05	0.000236	CcSEcCtD
Tacrolimus—Immune system disorder—Doxorubicin—uterine cancer	7.13e-05	0.000235	CcSEcCtD
Tacrolimus—Mediastinal disorder—Doxorubicin—uterine cancer	7.12e-05	0.000235	CcSEcCtD
Tacrolimus—Chills—Doxorubicin—uterine cancer	7.09e-05	0.000234	CcSEcCtD
Tacrolimus—Arrhythmia—Doxorubicin—uterine cancer	7.06e-05	0.000233	CcSEcCtD
Tacrolimus—Vision blurred—Epirubicin—uterine cancer	7e-05	0.000231	CcSEcCtD
Tacrolimus—Alopecia—Doxorubicin—uterine cancer	6.98e-05	0.00023	CcSEcCtD
Tacrolimus—Mental disorder—Doxorubicin—uterine cancer	6.92e-05	0.000228	CcSEcCtD
Tacrolimus—Ill-defined disorder—Epirubicin—uterine cancer	6.9e-05	0.000227	CcSEcCtD
Tacrolimus—Vomiting—Etoposide—uterine cancer	6.88e-05	0.000227	CcSEcCtD
Tacrolimus—Erythema—Doxorubicin—uterine cancer	6.88e-05	0.000227	CcSEcCtD
Tacrolimus—Malnutrition—Doxorubicin—uterine cancer	6.88e-05	0.000227	CcSEcCtD
Tacrolimus—Anaemia—Epirubicin—uterine cancer	6.87e-05	0.000226	CcSEcCtD
Tacrolimus—Agitation—Epirubicin—uterine cancer	6.83e-05	0.000225	CcSEcCtD
Tacrolimus—Rash—Etoposide—uterine cancer	6.82e-05	0.000225	CcSEcCtD
Tacrolimus—Dermatitis—Etoposide—uterine cancer	6.82e-05	0.000225	CcSEcCtD
Tacrolimus—Headache—Etoposide—uterine cancer	6.78e-05	0.000224	CcSEcCtD
Tacrolimus—Flatulence—Doxorubicin—uterine cancer	6.78e-05	0.000223	CcSEcCtD
Tacrolimus—Tension—Doxorubicin—uterine cancer	6.75e-05	0.000222	CcSEcCtD
Tacrolimus—Dysgeusia—Doxorubicin—uterine cancer	6.73e-05	0.000222	CcSEcCtD
Tacrolimus—Malaise—Epirubicin—uterine cancer	6.7e-05	0.000221	CcSEcCtD
Tacrolimus—Nervousness—Doxorubicin—uterine cancer	6.68e-05	0.00022	CcSEcCtD
Tacrolimus—Vertigo—Epirubicin—uterine cancer	6.68e-05	0.00022	CcSEcCtD
Tacrolimus—Syncope—Epirubicin—uterine cancer	6.66e-05	0.00022	CcSEcCtD
Tacrolimus—Leukopenia—Epirubicin—uterine cancer	6.65e-05	0.000219	CcSEcCtD
Tacrolimus—Back pain—Doxorubicin—uterine cancer	6.65e-05	0.000219	CcSEcCtD
Tacrolimus—Muscle spasms—Doxorubicin—uterine cancer	6.61e-05	0.000218	CcSEcCtD
Tacrolimus—Palpitations—Epirubicin—uterine cancer	6.57e-05	0.000217	CcSEcCtD
Tacrolimus—Loss of consciousness—Epirubicin—uterine cancer	6.53e-05	0.000215	CcSEcCtD
Tacrolimus—Cough—Epirubicin—uterine cancer	6.49e-05	0.000214	CcSEcCtD
Tacrolimus—Vision blurred—Doxorubicin—uterine cancer	6.48e-05	0.000214	CcSEcCtD
Tacrolimus—Convulsion—Epirubicin—uterine cancer	6.44e-05	0.000212	CcSEcCtD
Tacrolimus—Nausea—Etoposide—uterine cancer	6.43e-05	0.000212	CcSEcCtD
Tacrolimus—Hypertension—Epirubicin—uterine cancer	6.42e-05	0.000212	CcSEcCtD
Tacrolimus—Ill-defined disorder—Doxorubicin—uterine cancer	6.38e-05	0.00021	CcSEcCtD
Tacrolimus—Anaemia—Doxorubicin—uterine cancer	6.36e-05	0.00021	CcSEcCtD
Tacrolimus—Chest pain—Epirubicin—uterine cancer	6.33e-05	0.000209	CcSEcCtD
Tacrolimus—Myalgia—Epirubicin—uterine cancer	6.33e-05	0.000209	CcSEcCtD
Tacrolimus—Arthralgia—Epirubicin—uterine cancer	6.33e-05	0.000209	CcSEcCtD
Tacrolimus—Agitation—Doxorubicin—uterine cancer	6.32e-05	0.000208	CcSEcCtD
Tacrolimus—Anxiety—Epirubicin—uterine cancer	6.31e-05	0.000208	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	6.28e-05	0.000207	CcSEcCtD
Tacrolimus—Discomfort—Epirubicin—uterine cancer	6.25e-05	0.000206	CcSEcCtD
Tacrolimus—Malaise—Doxorubicin—uterine cancer	6.2e-05	0.000204	CcSEcCtD
Tacrolimus—Dry mouth—Epirubicin—uterine cancer	6.19e-05	0.000204	CcSEcCtD
Tacrolimus—Vertigo—Doxorubicin—uterine cancer	6.18e-05	0.000204	CcSEcCtD
Tacrolimus—Syncope—Doxorubicin—uterine cancer	6.17e-05	0.000203	CcSEcCtD
Tacrolimus—Leukopenia—Doxorubicin—uterine cancer	6.16e-05	0.000203	CcSEcCtD
Tacrolimus—Confusional state—Epirubicin—uterine cancer	6.12e-05	0.000202	CcSEcCtD
Tacrolimus—Palpitations—Doxorubicin—uterine cancer	6.08e-05	0.0002	CcSEcCtD
Tacrolimus—Oedema—Epirubicin—uterine cancer	6.07e-05	0.0002	CcSEcCtD
Tacrolimus—Anaphylactic shock—Epirubicin—uterine cancer	6.07e-05	0.0002	CcSEcCtD
Tacrolimus—Loss of consciousness—Doxorubicin—uterine cancer	6.04e-05	0.000199	CcSEcCtD
Tacrolimus—Infection—Epirubicin—uterine cancer	6.03e-05	0.000199	CcSEcCtD
Tacrolimus—Cough—Doxorubicin—uterine cancer	6e-05	0.000198	CcSEcCtD
Tacrolimus—Shock—Epirubicin—uterine cancer	5.97e-05	0.000197	CcSEcCtD
Tacrolimus—Convulsion—Doxorubicin—uterine cancer	5.96e-05	0.000196	CcSEcCtD
Tacrolimus—Nervous system disorder—Epirubicin—uterine cancer	5.95e-05	0.000196	CcSEcCtD
Tacrolimus—Thrombocytopenia—Epirubicin—uterine cancer	5.94e-05	0.000196	CcSEcCtD
Tacrolimus—Hypertension—Doxorubicin—uterine cancer	5.94e-05	0.000196	CcSEcCtD
Tacrolimus—Tachycardia—Epirubicin—uterine cancer	5.92e-05	0.000195	CcSEcCtD
Tacrolimus—Skin disorder—Epirubicin—uterine cancer	5.89e-05	0.000194	CcSEcCtD
Tacrolimus—Hyperhidrosis—Epirubicin—uterine cancer	5.86e-05	0.000193	CcSEcCtD
Tacrolimus—Arthralgia—Doxorubicin—uterine cancer	5.85e-05	0.000193	CcSEcCtD
Tacrolimus—Myalgia—Doxorubicin—uterine cancer	5.85e-05	0.000193	CcSEcCtD
Tacrolimus—Chest pain—Doxorubicin—uterine cancer	5.85e-05	0.000193	CcSEcCtD
Tacrolimus—Anxiety—Doxorubicin—uterine cancer	5.83e-05	0.000192	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	5.81e-05	0.000192	CcSEcCtD
Tacrolimus—Discomfort—Doxorubicin—uterine cancer	5.78e-05	0.000191	CcSEcCtD
Tacrolimus—Anorexia—Epirubicin—uterine cancer	5.78e-05	0.000191	CcSEcCtD
Tacrolimus—Dry mouth—Doxorubicin—uterine cancer	5.73e-05	0.000189	CcSEcCtD
Tacrolimus—Hypotension—Epirubicin—uterine cancer	5.67e-05	0.000187	CcSEcCtD
Tacrolimus—Confusional state—Doxorubicin—uterine cancer	5.66e-05	0.000187	CcSEcCtD
Tacrolimus—Oedema—Doxorubicin—uterine cancer	5.61e-05	0.000185	CcSEcCtD
Tacrolimus—Anaphylactic shock—Doxorubicin—uterine cancer	5.61e-05	0.000185	CcSEcCtD
Tacrolimus—Infection—Doxorubicin—uterine cancer	5.58e-05	0.000184	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Epirubicin—uterine cancer	5.53e-05	0.000182	CcSEcCtD
Tacrolimus—Shock—Doxorubicin—uterine cancer	5.52e-05	0.000182	CcSEcCtD
Tacrolimus—Nervous system disorder—Doxorubicin—uterine cancer	5.5e-05	0.000181	CcSEcCtD
Tacrolimus—Thrombocytopenia—Doxorubicin—uterine cancer	5.49e-05	0.000181	CcSEcCtD
Tacrolimus—Insomnia—Epirubicin—uterine cancer	5.49e-05	0.000181	CcSEcCtD
Tacrolimus—Tachycardia—Doxorubicin—uterine cancer	5.48e-05	0.000181	CcSEcCtD
Tacrolimus—Skin disorder—Doxorubicin—uterine cancer	5.45e-05	0.00018	CcSEcCtD
Tacrolimus—Paraesthesia—Epirubicin—uterine cancer	5.45e-05	0.00018	CcSEcCtD
Tacrolimus—Hyperhidrosis—Doxorubicin—uterine cancer	5.43e-05	0.000179	CcSEcCtD
Tacrolimus—Dyspnoea—Epirubicin—uterine cancer	5.41e-05	0.000178	CcSEcCtD
Tacrolimus—Somnolence—Epirubicin—uterine cancer	5.39e-05	0.000178	CcSEcCtD
Tacrolimus—Anorexia—Doxorubicin—uterine cancer	5.35e-05	0.000176	CcSEcCtD
Tacrolimus—Dyspepsia—Epirubicin—uterine cancer	5.34e-05	0.000176	CcSEcCtD
Tacrolimus—Decreased appetite—Epirubicin—uterine cancer	5.27e-05	0.000174	CcSEcCtD
Tacrolimus—Hypotension—Doxorubicin—uterine cancer	5.24e-05	0.000173	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Epirubicin—uterine cancer	5.24e-05	0.000173	CcSEcCtD
Tacrolimus—Fatigue—Epirubicin—uterine cancer	5.23e-05	0.000172	CcSEcCtD
Tacrolimus—Constipation—Epirubicin—uterine cancer	5.19e-05	0.000171	CcSEcCtD
Tacrolimus—Pain—Epirubicin—uterine cancer	5.19e-05	0.000171	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Doxorubicin—uterine cancer	5.11e-05	0.000169	CcSEcCtD
Tacrolimus—Insomnia—Doxorubicin—uterine cancer	5.08e-05	0.000167	CcSEcCtD
Tacrolimus—Paraesthesia—Doxorubicin—uterine cancer	5.04e-05	0.000166	CcSEcCtD
Tacrolimus—Dyspnoea—Doxorubicin—uterine cancer	5e-05	0.000165	CcSEcCtD
Tacrolimus—Feeling abnormal—Epirubicin—uterine cancer	5e-05	0.000165	CcSEcCtD
Tacrolimus—Somnolence—Doxorubicin—uterine cancer	4.99e-05	0.000165	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Epirubicin—uterine cancer	4.96e-05	0.000164	CcSEcCtD
Tacrolimus—Dyspepsia—Doxorubicin—uterine cancer	4.94e-05	0.000163	CcSEcCtD
Tacrolimus—Decreased appetite—Doxorubicin—uterine cancer	4.88e-05	0.000161	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Doxorubicin—uterine cancer	4.85e-05	0.00016	CcSEcCtD
Tacrolimus—Fatigue—Doxorubicin—uterine cancer	4.84e-05	0.00016	CcSEcCtD
Tacrolimus—Urticaria—Epirubicin—uterine cancer	4.82e-05	0.000159	CcSEcCtD
Tacrolimus—Constipation—Doxorubicin—uterine cancer	4.8e-05	0.000158	CcSEcCtD
Tacrolimus—Pain—Doxorubicin—uterine cancer	4.8e-05	0.000158	CcSEcCtD
Tacrolimus—Abdominal pain—Epirubicin—uterine cancer	4.79e-05	0.000158	CcSEcCtD
Tacrolimus—Body temperature increased—Epirubicin—uterine cancer	4.79e-05	0.000158	CcSEcCtD
Tacrolimus—Feeling abnormal—Doxorubicin—uterine cancer	4.62e-05	0.000152	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Doxorubicin—uterine cancer	4.59e-05	0.000151	CcSEcCtD
Tacrolimus—Hypersensitivity—Epirubicin—uterine cancer	4.47e-05	0.000147	CcSEcCtD
Tacrolimus—Urticaria—Doxorubicin—uterine cancer	4.46e-05	0.000147	CcSEcCtD
Tacrolimus—Abdominal pain—Doxorubicin—uterine cancer	4.44e-05	0.000146	CcSEcCtD
Tacrolimus—Body temperature increased—Doxorubicin—uterine cancer	4.44e-05	0.000146	CcSEcCtD
Tacrolimus—Asthenia—Epirubicin—uterine cancer	4.35e-05	0.000143	CcSEcCtD
Tacrolimus—Pruritus—Epirubicin—uterine cancer	4.29e-05	0.000141	CcSEcCtD
Tacrolimus—Diarrhoea—Epirubicin—uterine cancer	4.15e-05	0.000137	CcSEcCtD
Tacrolimus—Hypersensitivity—Doxorubicin—uterine cancer	4.13e-05	0.000136	CcSEcCtD
Tacrolimus—ABCB1—Metabolism—NDUFB11—uterine cancer	4.12e-05	0.000333	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—AKT1—uterine cancer	4.12e-05	0.000333	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—AKT1—uterine cancer	4.1e-05	0.000332	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CDKN1B—uterine cancer	4.1e-05	0.000332	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—ERBB2—uterine cancer	4.09e-05	0.000331	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CDKN2B—uterine cancer	4.06e-05	0.000328	CbGpPWpGaD
Tacrolimus—Asthenia—Doxorubicin—uterine cancer	4.03e-05	0.000133	CcSEcCtD
Tacrolimus—Dizziness—Epirubicin—uterine cancer	4.01e-05	0.000132	CcSEcCtD
Tacrolimus—CYP3A7—Metabolism—AKR1C1—uterine cancer	4.01e-05	0.000324	CbGpPWpGaD
Tacrolimus—ABCB1—HIF-1-alpha transcription factor network—AKT1—uterine cancer	3.98e-05	0.000321	CbGpPWpGaD
Tacrolimus—Pruritus—Doxorubicin—uterine cancer	3.97e-05	0.000131	CcSEcCtD
Tacrolimus—CYP3A5—Metabolism—AKR1B1—uterine cancer	3.95e-05	0.000319	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—STAR—uterine cancer	3.95e-05	0.000319	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IGF1R—uterine cancer	3.94e-05	0.000319	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—ESR1—uterine cancer	3.9e-05	0.000315	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—AKT1—uterine cancer	3.88e-05	0.000314	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CTNNB1—uterine cancer	3.88e-05	0.000313	CbGpPWpGaD
Tacrolimus—Vomiting—Epirubicin—uterine cancer	3.86e-05	0.000127	CcSEcCtD
Tacrolimus—Diarrhoea—Doxorubicin—uterine cancer	3.84e-05	0.000127	CcSEcCtD
Tacrolimus—Rash—Epirubicin—uterine cancer	3.82e-05	0.000126	CcSEcCtD
Tacrolimus—Dermatitis—Epirubicin—uterine cancer	3.82e-05	0.000126	CcSEcCtD
Tacrolimus—MTOR—Signaling by NGF—KRAS—uterine cancer	3.81e-05	0.000308	CbGpPWpGaD
Tacrolimus—Headache—Epirubicin—uterine cancer	3.8e-05	0.000125	CcSEcCtD
Tacrolimus—PPP3CA—Disease—CDKN1B—uterine cancer	3.79e-05	0.000306	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—PTEN—uterine cancer	3.78e-05	0.000305	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CDH1—uterine cancer	3.77e-05	0.000305	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—AKT1—uterine cancer	3.74e-05	0.000302	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—uterine cancer	3.72e-05	0.0003	CbGpPWpGaD
Tacrolimus—Dizziness—Doxorubicin—uterine cancer	3.71e-05	0.000122	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—SMAD3—uterine cancer	3.71e-05	0.0003	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—SOCS3—uterine cancer	3.69e-05	0.000298	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—NRAS—uterine cancer	3.69e-05	0.000298	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—TP53—uterine cancer	3.61e-05	0.000292	CbGpPWpGaD
Tacrolimus—Nausea—Epirubicin—uterine cancer	3.6e-05	0.000119	CcSEcCtD
Tacrolimus—PPP3CA—Immune System—EP300—uterine cancer	3.6e-05	0.000291	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—CTNNB1—uterine cancer	3.58e-05	0.000289	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—RRM2—uterine cancer	3.57e-05	0.000289	CbGpPWpGaD
Tacrolimus—Vomiting—Doxorubicin—uterine cancer	3.57e-05	0.000118	CcSEcCtD
Tacrolimus—Rash—Doxorubicin—uterine cancer	3.54e-05	0.000117	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—FGFR2—uterine cancer	3.54e-05	0.000286	CbGpPWpGaD
Tacrolimus—Dermatitis—Doxorubicin—uterine cancer	3.54e-05	0.000117	CcSEcCtD
Tacrolimus—Headache—Doxorubicin—uterine cancer	3.52e-05	0.000116	CcSEcCtD
Tacrolimus—MTOR—Signaling by NGF—PIK3CA—uterine cancer	3.5e-05	0.000283	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—PTEN—uterine cancer	3.49e-05	0.000282	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—DCN—uterine cancer	3.47e-05	0.00028	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	3.46e-05	0.000279	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CCL2—uterine cancer	3.43e-05	0.000278	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—AKR1B1—uterine cancer	3.4e-05	0.000275	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—STAR—uterine cancer	3.4e-05	0.000275	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—NRAS—uterine cancer	3.37e-05	0.000272	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	3.36e-05	0.000272	CbGpPWpGaD
Tacrolimus—Nausea—Doxorubicin—uterine cancer	3.33e-05	0.00011	CcSEcCtD
Tacrolimus—PPP3CA—Disease—EP300—uterine cancer	3.33e-05	0.000269	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—ERBB2—uterine cancer	3.32e-05	0.000268	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—AKR1C3—uterine cancer	3.27e-05	0.000264	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—CYP11A1—uterine cancer	3.27e-05	0.000264	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CDKN2B—uterine cancer	3.26e-05	0.000264	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—HRAS—uterine cancer	3.24e-05	0.000262	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	3.2e-05	0.000259	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PGR—uterine cancer	3.19e-05	0.000258	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—ERBB2—uterine cancer	3.18e-05	0.000257	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—KRAS—uterine cancer	3.17e-05	0.000257	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—ERBB2—uterine cancer	3.17e-05	0.000256	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—NRAS—uterine cancer	3.11e-05	0.000251	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—POLD1—uterine cancer	3.1e-05	0.00025	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—AKR1C3—uterine cancer	3.09e-05	0.000249	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—FGFR2—uterine cancer	3.08e-05	0.000249	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—CDKN1B—uterine cancer	3.07e-05	0.000248	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—YWHAE—uterine cancer	3.04e-05	0.000246	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—ESR1—uterine cancer	3.03e-05	0.000245	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	3.02e-05	0.000245	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—AKR1B1—uterine cancer	2.98e-05	0.000241	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—STAR—uterine cancer	2.98e-05	0.000241	CbGpPWpGaD
Tacrolimus—MTOR—Disease—SMAD3—uterine cancer	2.98e-05	0.000241	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CDKN1B—uterine cancer	2.95e-05	0.000238	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	2.95e-05	0.000238	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—CDKN1B—uterine cancer	2.94e-05	0.000237	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—PIK3CA—uterine cancer	2.92e-05	0.000236	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—FBXW7—uterine cancer	2.91e-05	0.000236	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—CTNNB1—uterine cancer	2.9e-05	0.000235	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—KRAS—uterine cancer	2.9e-05	0.000234	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—AKR1C1—uterine cancer	2.9e-05	0.000234	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—ERBB2—uterine cancer	2.86e-05	0.000231	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—AKT1—uterine cancer	2.86e-05	0.000231	CbGpPWpGaD
Tacrolimus—MTOR—Disease—FGFR2—uterine cancer	2.84e-05	0.00023	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—PTEN—uterine cancer	2.83e-05	0.000229	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	2.81e-05	0.000227	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—CTNNB1—uterine cancer	2.77e-05	0.000224	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MTHFR—uterine cancer	2.73e-05	0.000221	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CXCL8—uterine cancer	2.72e-05	0.00022	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—PTEN—uterine cancer	2.72e-05	0.00022	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—VEGFA—uterine cancer	2.7e-05	0.000219	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—PTEN—uterine cancer	2.7e-05	0.000219	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—HRAS—uterine cancer	2.7e-05	0.000218	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—EP300—uterine cancer	2.7e-05	0.000218	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—KRAS—uterine cancer	2.68e-05	0.000216	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—POLD1—uterine cancer	2.67e-05	0.000216	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—PIK3CA—uterine cancer	2.66e-05	0.000215	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CCL2—uterine cancer	2.66e-05	0.000215	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	2.66e-05	0.000215	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CDKN1B—uterine cancer	2.65e-05	0.000214	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—RRM2—uterine cancer	2.58e-05	0.000209	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—EP300—uterine cancer	2.58e-05	0.000208	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—STK11—uterine cancer	2.55e-05	0.000206	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NDUFB11—uterine cancer	2.54e-05	0.000205	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SRD5A2—uterine cancer	2.54e-05	0.000205	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—NRAS—uterine cancer	2.52e-05	0.000204	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—DCN—uterine cancer	2.51e-05	0.000203	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CTNNB1—uterine cancer	2.51e-05	0.000203	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—AKR1C1—uterine cancer	2.5e-05	0.000202	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—HRAS—uterine cancer	2.47e-05	0.000199	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—PIK3CA—uterine cancer	2.46e-05	0.000199	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—PTEN—uterine cancer	2.44e-05	0.000197	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—NRAS—uterine cancer	2.42e-05	0.000196	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—NRAS—uterine cancer	2.41e-05	0.000195	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—STK11—uterine cancer	2.4e-05	0.000194	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—CYP19A1—uterine cancer	2.4e-05	0.000194	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SOCS3—uterine cancer	2.39e-05	0.000193	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—AKT1—uterine cancer	2.38e-05	0.000193	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CYP11A1—uterine cancer	2.36e-05	0.000191	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—POLD1—uterine cancer	2.34e-05	0.000189	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—EP300—uterine cancer	2.33e-05	0.000188	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CDH1—uterine cancer	2.29e-05	0.000185	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CDKN2B—uterine cancer	2.28e-05	0.000185	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—HRAS—uterine cancer	2.28e-05	0.000184	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	2.26e-05	0.000183	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—AKR1C3—uterine cancer	2.23e-05	0.00018	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—RRM2—uterine cancer	2.22e-05	0.00018	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—ERBB2—uterine cancer	2.22e-05	0.000179	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IGF1R—uterine cancer	2.22e-05	0.000179	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—VEGFA—uterine cancer	2.21e-05	0.000178	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—AKR1C1—uterine cancer	2.19e-05	0.000177	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—NRAS—uterine cancer	2.18e-05	0.000176	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—AKT1—uterine cancer	2.18e-05	0.000176	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—KRAS—uterine cancer	2.17e-05	0.000176	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—DCN—uterine cancer	2.16e-05	0.000175	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	2.11e-05	0.000171	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CXCL8—uterine cancer	2.11e-05	0.00017	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—KRAS—uterine cancer	2.09e-05	0.000169	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SMAD3—uterine cancer	2.08e-05	0.000169	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	2.08e-05	0.000168	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—KRAS—uterine cancer	2.08e-05	0.000168	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CDKN1B—uterine cancer	2.06e-05	0.000166	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CYP11A1—uterine cancer	2.03e-05	0.000164	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	2.01e-05	0.000163	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—AKT1—uterine cancer	2.01e-05	0.000162	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—PIK3CA—uterine cancer	2e-05	0.000161	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—FGFR2—uterine cancer	1.99e-05	0.000161	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—RRM2—uterine cancer	1.95e-05	0.000158	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CTNNB1—uterine cancer	1.94e-05	0.000157	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—ERBB2—uterine cancer	1.93e-05	0.000156	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—AKR1C3—uterine cancer	1.92e-05	0.000155	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—PIK3CA—uterine cancer	1.92e-05	0.000155	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—PIK3CA—uterine cancer	1.91e-05	0.000154	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PTEN—uterine cancer	1.89e-05	0.000153	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—DCN—uterine cancer	1.89e-05	0.000153	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—KRAS—uterine cancer	1.88e-05	0.000152	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—HRAS—uterine cancer	1.85e-05	0.000149	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—AKR1B1—uterine cancer	1.84e-05	0.000148	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—STAR—uterine cancer	1.84e-05	0.000148	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—MTHFR—uterine cancer	1.81e-05	0.000146	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—EP300—uterine cancer	1.81e-05	0.000146	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CDKN1B—uterine cancer	1.79e-05	0.000145	CbGpPWpGaD
Tacrolimus—MTOR—Disease—ERBB2—uterine cancer	1.78e-05	0.000144	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CYP11A1—uterine cancer	1.78e-05	0.000144	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HRAS—uterine cancer	1.77e-05	0.000143	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—HRAS—uterine cancer	1.76e-05	0.000143	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—STK11—uterine cancer	1.74e-05	0.00014	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CYP19A1—uterine cancer	1.74e-05	0.00014	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—AKT1—uterine cancer	1.73e-05	0.000139	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—PIK3CA—uterine cancer	1.72e-05	0.000139	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—VEGFA—uterine cancer	1.71e-05	0.000138	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—ESR1—uterine cancer	1.7e-05	0.000138	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	1.7e-05	0.000137	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CTNNB1—uterine cancer	1.69e-05	0.000137	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—NRAS—uterine cancer	1.69e-05	0.000137	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—AKR1C3—uterine cancer	1.68e-05	0.000136	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TP53—uterine cancer	1.67e-05	0.000135	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CDKN1B—uterine cancer	1.65e-05	0.000133	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PTEN—uterine cancer	1.65e-05	0.000133	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—AKT1—uterine cancer	1.63e-05	0.000132	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—HRAS—uterine cancer	1.59e-05	0.000129	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—EP300—uterine cancer	1.57e-05	0.000127	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—AKT1—uterine cancer	1.57e-05	0.000127	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CTNNB1—uterine cancer	1.56e-05	0.000126	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—AKT1—uterine cancer	1.56e-05	0.000126	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PTEN—uterine cancer	1.52e-05	0.000123	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCL2—uterine cancer	1.5e-05	0.000121	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—STK11—uterine cancer	1.5e-05	0.000121	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CYP19A1—uterine cancer	1.5e-05	0.000121	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—EP300—uterine cancer	1.47e-05	0.000119	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—NRAS—uterine cancer	1.47e-05	0.000119	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—KRAS—uterine cancer	1.45e-05	0.000118	CbGpPWpGaD
Tacrolimus—MTOR—Disease—EP300—uterine cancer	1.45e-05	0.000117	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—POLD1—uterine cancer	1.44e-05	0.000116	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—AKT1—uterine cancer	1.41e-05	0.000114	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.41e-05	0.000114	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—VEGFA—uterine cancer	1.39e-05	0.000113	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—NRAS—uterine cancer	1.38e-05	0.000111	CbGpPWpGaD
Tacrolimus—MTOR—Disease—NRAS—uterine cancer	1.36e-05	0.00011	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—AKR1C1—uterine cancer	1.35e-05	0.000109	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.34e-05	0.000108	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PIK3CA—uterine cancer	1.34e-05	0.000108	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—STK11—uterine cancer	1.31e-05	0.000106	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CYP19A1—uterine cancer	1.31e-05	0.000106	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—MTHFR—uterine cancer	1.31e-05	0.000106	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TP53—uterine cancer	1.29e-05	0.000104	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—KRAS—uterine cancer	1.26e-05	0.000102	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—ERBB2—uterine cancer	1.25e-05	0.000101	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—HRAS—uterine cancer	1.24e-05	9.99e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—RRM2—uterine cancer	1.2e-05	9.71e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—KRAS—uterine cancer	1.19e-05	9.58e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CXCL8—uterine cancer	1.18e-05	9.57e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—KRAS—uterine cancer	1.17e-05	9.44e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—DCN—uterine cancer	1.17e-05	9.42e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PIK3CA—uterine cancer	1.16e-05	9.39e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CDKN1B—uterine cancer	1.16e-05	9.35e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—MTHFR—uterine cancer	1.12e-05	9.09e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP11A1—uterine cancer	1.1e-05	8.88e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CTNNB1—uterine cancer	1.09e-05	8.83e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—AKT1—uterine cancer	1.09e-05	8.82e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PIK3CA—uterine cancer	1.09e-05	8.8e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HRAS—uterine cancer	1.08e-05	8.69e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PIK3CA—uterine cancer	1.07e-05	8.67e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PTEN—uterine cancer	1.06e-05	8.61e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TP53—uterine cancer	1.05e-05	8.51e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—AKR1C3—uterine cancer	1.04e-05	8.38e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—EP300—uterine cancer	1.02e-05	8.21e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—HRAS—uterine cancer	1.01e-05	8.14e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PTEN—uterine cancer	1.01e-05	8.13e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—HRAS—uterine cancer	9.93e-06	8.02e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	9.91e-06	8.01e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—MTHFR—uterine cancer	9.86e-06	7.97e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—VEGFA—uterine cancer	9.62e-06	7.77e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—EP300—uterine cancer	9.59e-06	7.75e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NRAS—uterine cancer	9.5e-06	7.68e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—AKT1—uterine cancer	9.49e-06	7.67e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—AKT1—uterine cancer	8.89e-06	7.19e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—AKT1—uterine cancer	8.76e-06	7.08e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KRAS—uterine cancer	8.18e-06	6.61e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP19A1—uterine cancer	8.08e-06	6.53e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—STK11—uterine cancer	8.08e-06	6.53e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CA—uterine cancer	7.51e-06	6.07e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TP53—uterine cancer	7.27e-06	5.87e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTEN—uterine cancer	7.27e-06	5.87e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CA—uterine cancer	7.09e-06	5.73e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—HRAS—uterine cancer	6.95e-06	5.62e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—EP300—uterine cancer	6.93e-06	5.6e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTEN—uterine cancer	6.26e-06	5.06e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—AKT1—uterine cancer	6.14e-06	4.96e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—MTHFR—uterine cancer	6.07e-06	4.91e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—EP300—uterine cancer	5.97e-06	4.82e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—AKT1—uterine cancer	5.79e-06	4.68e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTEN—uterine cancer	5.48e-06	4.43e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—EP300—uterine cancer	5.23e-06	4.23e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CA—uterine cancer	5.13e-06	4.14e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CA—uterine cancer	4.41e-06	3.57e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—AKT1—uterine cancer	4.19e-06	3.38e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CA—uterine cancer	3.87e-06	3.13e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—AKT1—uterine cancer	3.61e-06	2.92e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTEN—uterine cancer	3.38e-06	2.73e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—EP300—uterine cancer	3.22e-06	2.6e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—AKT1—uterine cancer	3.16e-06	2.55e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CA—uterine cancer	2.38e-06	1.93e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—AKT1—uterine cancer	1.95e-06	1.57e-05	CbGpPWpGaD
